Suppr
超能文献

ALS issues in clinical trials. Statistical issues.

作者信息

Levin Bruce

机构信息

Columbia, NY, USA.

出版信息

Amyotroph Lateral Scler Other Motor Neuron Disord. 2004 Sep;5 Suppl 1:43-5. doi: 10.1080/17434470410019799.

DOI:10.1080/17434470410019799

PMID:15512870

Abstract

摘要

相似文献

ALS issues in clinical trials. Statistical issues.

Amyotroph Lateral Scler Other Motor Neuron Disord. 2004 Sep;5 Suppl 1:43-5. doi: 10.1080/17434470410019799.

What is next in ALS clinical trials?

Neurology. 2007 Aug 21;69(8):719-20. doi: 10.1212/01.wnl.0000271093.41793.ff.

ALS issues in clinical trials. Missing data.

Amyotroph Lateral Scler Other Motor Neuron Disord. 2004 Sep;5 Suppl 1:48-51. doi: 10.1080/17434470410019753.

Selecting promising ALS therapies in clinical trials.

Neurology. 2006 Nov 28;67(10):1748-51. doi: 10.1212/01.wnl.0000244464.73221.13.

Improving efficiency of ALS clinical trials using lead-in designs.

Amyotroph Lateral Scler Other Motor Neuron Disord. 2004 Sep;5 Suppl 1:57-60. doi: 10.1080/17434470410019997.

The biopharmaceutical industry and new drugs for amyotrophic lateral sclerosis.

Adv Neurol. 1995;68:263-9; discussion 271-5.

Baseline disease characteristics.

Amyotroph Lateral Scler Other Motor Neuron Disord. 2004 Sep;5 Suppl 1:64-7. doi: 10.1080/17434470410019924.

ALS trial design: expectation and reality.

Amyotroph Lateral Scler Other Motor Neuron Disord. 2004 Sep;5 Suppl 1:52-4. doi: 10.1080/17434470410019979.

Designing clinical trials in amyotrophic lateral sclerosis.

Phys Med Rehabil Clin N Am. 2008 Aug;19(3):495-508, ix. doi: 10.1016/j.pmr.2008.02.002.

Improving efficiency of ALS clinical trials: a sponsor's perspective.

Amyotroph Lateral Scler Other Motor Neuron Disord. 2002;3 Suppl 1:S7-8. doi: 10.1080/146608202320374138.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

ALS issues in clinical trials. Statistical issues.

Amyotroph Lateral Scler Other Motor Neuron Disord. 2004 Sep;5 Suppl 1:43-5. doi: 10.1080/17434470410019799.

What is next in ALS clinical trials?

Neurology. 2007 Aug 21;69(8):719-20. doi: 10.1212/01.wnl.0000271093.41793.ff.

ALS issues in clinical trials. Missing data.

Amyotroph Lateral Scler Other Motor Neuron Disord. 2004 Sep;5 Suppl 1:48-51. doi: 10.1080/17434470410019753.

Selecting promising ALS therapies in clinical trials.

Neurology. 2006 Nov 28;67(10):1748-51. doi: 10.1212/01.wnl.0000244464.73221.13.

Improving efficiency of ALS clinical trials using lead-in designs.

Amyotroph Lateral Scler Other Motor Neuron Disord. 2004 Sep;5 Suppl 1:57-60. doi: 10.1080/17434470410019997.

The biopharmaceutical industry and new drugs for amyotrophic lateral sclerosis.

Adv Neurol. 1995;68:263-9; discussion 271-5.

Baseline disease characteristics.

Amyotroph Lateral Scler Other Motor Neuron Disord. 2004 Sep;5 Suppl 1:64-7. doi: 10.1080/17434470410019924.

ALS trial design: expectation and reality.

Amyotroph Lateral Scler Other Motor Neuron Disord. 2004 Sep;5 Suppl 1:52-4. doi: 10.1080/17434470410019979.

Designing clinical trials in amyotrophic lateral sclerosis.

Phys Med Rehabil Clin N Am. 2008 Aug;19(3):495-508, ix. doi: 10.1016/j.pmr.2008.02.002.

Improving efficiency of ALS clinical trials: a sponsor's perspective.

Amyotroph Lateral Scler Other Motor Neuron Disord. 2002;3 Suppl 1:S7-8. doi: 10.1080/146608202320374138.

Suppr超能文献

ALS issues in clinical trials. Statistical issues.

作者信息

机构信息

出版信息

相似文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

Suppr
超能文献